Carsten Dirksen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3436160/publications.pdf

Version: 2024-02-01

42	3,414	279798	289244
papers	citations	23 h-index	40 g-index

42	42	42	3587
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Changes in Gastrointestinal Hormone Responses, Insulin Sensitivity, and Beta-Cell Function Within 2 Weeks After Gastric Bypass in Non-diabetic Subjects. Obesity Surgery, 2012, 22, 1084-1096.	2.1	287
2	Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance. American Journal of Physiology - Endocrinology and Metabolism, 2012, 303, E122-E131.	3.5	274
3	Exaggerated Glucagon-Like Peptide 1 Response Is Important for Improved Î²-Cell Function and Glucose Tolerance After Roux-en-Y Gastric Bypass in Patients With Type 2 Diabetes. Diabetes, 2013, 62, 3044-3052.	0.6	262
4	Roux-en-Y gastric bypass surgery of morbidly obese patients induces swift and persistent changes of the individual gut microbiota. Genome Medicine, 2016, 8, 67.	8.2	260
5	Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery. Lancet Diabetes and Endocrinology,the, 2014, 2, 152-164.	11.4	248
6	Early Enhancements of Hepatic and Later of Peripheral Insulin Sensitivity Combined With Increased Postprandial Insulin Secretion Contribute to Improved Glycemic Control After Roux-en-Y Gastric Bypass. Diabetes, 2014, 63, 1725-1737.	0.6	220
7	Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-en-Y gastric bypass. International Journal of Obesity, 2013, 37, 1452-1459.	3.4	209
8	Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass. Diabetologia, 2012, 55, 1890-1901.	6.3	208
9	Fast pouch emptying, delayed small intestinal transit, and exaggerated gut hormone responses after Rouxâ€enâ€Y gastric bypass. Neurogastroenterology and Motility, 2013, 25, 346.	3.0	150
10	Mechanisms in bariatric surgery: Gut hormones, diabetes resolution, and weight loss. Surgery for Obesity and Related Diseases, 2018, 14, 708-714.	1.2	144
11	Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery. International Journal of Obesity, 2016, 40, 1699-1706.	3.4	135
12	Postprandial Diabetic Glucose Tolerance Is Normalized by Gastric Bypass Feeding as Opposed to Gastric Feeding and Is Associated With Exaggerated GLP-1 Secretion. Diabetes Care, 2010, 33, 375-377.	8.6	105
13	Effects of gastric bypass surgery on glucose absorption and metabolism during a mixed meal in glucose-tolerant individuals. Diabetologia, 2013, 56, 2250-2254.	6.3	100
14	Postprandial Nutrient Handling and Gastrointestinal Hormone Secretion After Roux-en-Y Gastric Bypass vs Sleeve Gastrectomy. Gastroenterology, 2019, 156, 1627-1641.e1.	1.3	99
15	Improvements in Glucose Metabolism Early After Gastric Bypass Surgery Are Not Explained by Increases in Total Bile Acids and Fibroblast Growth Factor 19 Concentrations. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E396-E406.	3.6	89
16	Exaggerated release and preserved insulinotropic action of glucagon-like peptide-1 underlie insulin hypersecretion in glucose-tolerant individuals after Roux-en-Y gastric bypass. Diabetologia, 2013, 56, 2679-2687.	6.3	82
17	Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss. International Journal of Obesity, 2015, 39, 834-841.	3.4	71
18	Increased Hepatic Insulin Clearance After Roux-en-Y Gastric Bypass. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1066-E1071.	3.6	66

#	Article	IF	Citations
19	Immediate enhancement of first-phase insulin secretion and unchanged glucose effectiveness in patients with type 2 diabetes after Roux-en-Y gastric bypass. American Journal of Physiology - Endocrinology and Metabolism, 2015, 308, E535-E544.	3.5	62
20	Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery. American Journal of Physiology - Endocrinology and Metabolism, 2016, 310, E505-E514.	3.5	56
21	Accelerated protein digestion and amino acid absorption after Roux-en-Y gastric bypass. American Journal of Clinical Nutrition, 2015, 102, 600-607.	4.7	50
22	Enhanced insulin signaling in human skeletal muscle and adipose tissue following gastric bypass surgery. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2015, 309, R510-R524.	1.8	42
23	Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production. Cell Reports, 2017, 21, 1452-1460.	6.4	28
24	Improved thymic index, density and output in HIV-infected patients following low-dose growth hormone therapy: a placebo controlled study. Aids, 2009, 23, 2123-2131.	2.2	24
25	No Islet Cell Hyperfunction, but Altered Gut-Islet Regulation and Postprandial Hypoglycemia in Glucose-Tolerant Patients 3ÂYears After Gastric Bypass Surgery. Obesity Surgery, 2016, 26, 2263-2267.	2.1	20
26	Reduction in cardiovascular risk factors and insulin dose, but no beta-cell regeneration 1 year after Roux-en-Y gastric bypass in an obese patient with type 1 diabetes: A case report. Obesity Research and Clinical Practice, 2013, 7, e269-e274.	1.8	18
27	Variable reliability of surrogate measures of insulin sensitivity after Roux-en-Y gastric bypass. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2017, 312, R797-R805.	1.8	15
28	Augmented GLP-1 Secretion as Seen After Gastric Bypass May Be Obtained by Delaying Carbohydrate Digestion. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3233-3244.	3.6	15
29	Bilio-enteric flow and plasma concentrations of bile acids after gastric bypass and sleeve gastrectomy. International Journal of Obesity, 2020, 44, 1872-1883.	3.4	13
30	The effect of acute dual SGLT1/SGLT2 inhibition on incretin release and glucose metabolism after gastric bypass surgery. American Journal of Physiology - Endocrinology and Metabolism, 2020, 318, E956-E964.	3.5	13
31	Energy intake, gastrointestinal transit, and gut hormone release in response to oral triglycerides and fatty acids in men with and without severe obesity. American Journal of Physiology - Renal Physiology, 2019, 316, G332-G337.	3.4	10
32	Intestinal sensing and handling of dietary lipids in gastric bypassâ€“operated patients and matched controls. American Journal of Clinical Nutrition, 2020, 111, 28-41.	4.7	7
33	On measurements of glucagon secretion in healthy, obese, and Roux-en-Y gastric bypass operated individuals using sandwich ELISA. Scandinavian Journal of Clinical and Laboratory Investigation, 2022, 82, 75-83.	1.2	7
34	Sustained Improvements in Glucose Metabolism Late After Roux-En-Y Gastric Bypass Surgery in Patients with and Without Preoperative Diabetes. Scientific Reports, 2019, 9, 15154.	3.3	6
35	Systems Signatures Reveal Unique Remission-path of Type 2 Diabetes Following Roux-en-Y Gastric Bypass Surgery. EBioMedicine, 2018, 28, 234-240.	6.1	5
36	Effect of Meal Texture on Postprandial Glucose Excursions and Gut Hormones After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy. Frontiers in Nutrition, 2022, 9, 889710.	3.7	4

#	Article	IF	Citations
37	Gastric bypass and duodenal and gastric feeding: a comment to Hansen et al.. American Journal of Physiology - Renal Physiology, 2011, 301, G938-G939.	3.4	3
38	Gastrointestinal motility, gut hormone secretion, and energy intake after oral loads of free fatty acid or triglyceride in older and middle-aged men. Appetite, 2019, 132, 18-24.	3.7	3
39	T-lymphocyte subset dynamics in well-treated HIV-infected men during a bout of exhausting exercise. Infectious Diseases, 2015, 47, 919-923.	2.8	2
40	Neurotensin secretion after Rouxâ€enâ€Y gastric bypass, sleeve gastrectomy, and truncal vagotomy with pyloroplasty. Neurogastroenterology and Motility, 2021, , e14210.	3.0	2
41	The 8 th meeting of North European Young Diabetologists. Diabetic Medicine, 2020, 37, 1403-1403.	2.3	0
42	The substantial costs to society associated with obesity â€“ a Danish register-based study based on 2002-2018 data. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, , 1-11.	1.4	0